Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel
NASDAQ:ENGN

enGene Q1 2026 Earnings Report

enGene logo
$1.64 -0.09 (-4.94%)
As of 12:42 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

enGene EPS Results

Actual EPS
-$0.44
Consensus EPS
-$0.55
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

enGene Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

enGene Announcement Details

Quarter
Q1 2026
Date
3/9/2026
Time
Before Market Opens
Conference Call Date
Monday, March 9, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

enGene's Q2 2026 earnings is estimated for Thursday, June 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, June 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

enGene's Q1 2026 Press ReleasePress Release
(8-K)
enGene's Q1 2026 Quarterly reportQuarterly report
(10-Q)

enGene Earnings Headlines

Four sub-$1,000 methods for boosting most engines' horsepower, ranked by easiness
 |  msn.comhttps://www.msn.com/en-us/news/technology/four-sub-1-000-methods-for-boosting-most-engines-horsepower-ranked-by-easiness/ar-AA22Hr5Q
This groundbreaking hydrogen engine could rival diesel power without the emissions
 |  msn.comhttps://www.msn.com/en-us/money/general/this-groundbreaking-hydrogen-engine-could-rival-diesel-power-without-the-emissions/ar-AA22H1b1
$1,170 monthly from silver
I've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens with silver. But it is now possible thanks to a new ETF that delivers the best of worlds.tc pixel
May 8 at 1:00 AM  |  Investors Alley (Ad)
How far can an airplane glide if it loses its engines?
May 7 at 7:24 PM  |  msn.comhttps://www.msn.com/en-us/travel/news/how-far-can-an-airplane-glide-if-it-loses-its-engines/ar-AA22ztEn
enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
May 7 at 3:35 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3290474/0/en/engene-therapeutics-inc-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-more-information-about-potentially-recovering-their-losses.html
Why is the Ford 427 V8 engine called the side-oiler?
May 7 at 2:23 PM  |  msn.comhttps://www.msn.com/en-us/autos/enthusiasts/why-is-the-ford-427-v8-engine-called-the-side-oiler/ar-AA22BWrW
See More enGene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like enGene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enGene and other key companies, straight to your email.

About enGene

enGene (NASDAQ:ENGN) is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

View enGene Profile
Earnings Tools